Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

Part of paid clinical trials in Albany, New York.

Sponsor
Albany Research Institute, Inc.
Study ID
NCT05616923
Phase
PHASE1
Status
Completed

Conditions

  • Rosacea, Erythematotelangiectatic

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Trametinib — DRUG
    Topical cream containing 0.1 mg/g trametinib

Study Details

This is a prospective, vehicle controlled, double blinded study to evaluate the safety and potential efficacy of a topical formulation of a MEK inhibitor in patients with erythematotelangiectatic rosacea

Key Dates

Start date
Nov 1, 2021
Status verified
May 2023
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022

Study Design

Enrollment
12 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Trametinib
    Cheek describing the active compound (topical cream containing 0.1 mg/g trametinib)
  • Placebo Comparator: Vehicle
    Cheek receiving cream without active compound (topical cream lacking active ingredient)

Primary Outcome Measure

Change in dermatologic score [ Time Frame: 22 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Samuel S. Stratton VA Medical CenterAlbanyNew York12208-

Find similar trials in Albany, NY

By research site
Samuel S. Stratton VA Medical Center· Albany, NY

Related Studies